VEGF-A expression correlates with TP53 mutations in non-small cell lung cancer: Implications for antiangiogenesis therapy

Cancer Research

Volumn 75, Issue 7, 2015, Pages 1187-1190

  Schwaederlé, Maria ^a   Lazar, Vladimir ^b   Validire, Pierre ^c   Hansson, Johan ^d   Lacroix, Ludovic ^b   Soria, Jean Charles ^b   Pawitan, Yudi ^d   Kurzrock, Razelle ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Montsouris Institute   (France)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN A; ANGIOGENESIS INHIBITOR; PROTEIN P53; TP53 PROTEIN, HUMAN; TRANSCRIPTOME; VEGFA PROTEIN, HUMAN;

ANTIANGIOGENIC THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE REGRESSION; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; ONCOGENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ALIGNMENT; TP53 GENE; TRANSCRIPTOMICS; ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; GENETICS; LUNG NEOPLASMS; METABOLISM; MUTATION;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; CARCINOMA, SQUAMOUS CELL; HUMANS; LUNG NEOPLASMS; MUTATION; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84929334169     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2305     Document Type: Article

References (20)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220-41.
2. Lazar V, Suo C, Orear C, van den Oord J, Balogh Z, Guegan J, et al. Integrated molecular portrait of non-small cell lung cancers. BMC Med Genomics 2013;6:53.
3. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
4. Avastin (bevacizumab) price [Internet]. Available from: http://www.newsmedical.net/health/Avastin-(Bevacizumab)-Price.aspx
5. Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, et al. P53 Mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget 2013;4:705-14.
6. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxiainducible factor 1alpha. Genes Dev 2000;14:34-44.
7. Narendran A, Ganjavi H, Morson N, Connor A, Barlow JW, Keystone E, et al. Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. Exp Hematol 2003;31:693-701.
8. Lambrechts D, Lenz H-J, de Haas S, Carmeliet P, Scherer SJ. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol Off J Am Soc Clin Oncol 2013;31:1219-30.
9. Bellou S, Pentheroudakis G, Murphy C, Fotsis T. Anti-angiogenesis in cancer therapy: Hercules and hydra. Cancer Lett 2013;338:219-28.
10. Yuan A, Yu C-J, Luh K-T, Kuo S-H, Lee Y-C, Yang P-C. Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 2002;20:900-10.
11. Niklińska W, Burzykowski T, Chyczewski L, Nikliński J. Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis. Lung Cancer Amst Neth 2001;34:S59-64.
12. Farhang Ghahremani M, Goossens S, Haigh JJ. The p53 family and VEGF regulation: "It's complicated." Cell Cycle Georget Tex 2013;12:1331-2.
13. Huang C, Kohno N, Inufusa H, Kodama K, Taki T, Miyake M. Overexpression of bax associated with mutations in the loop-sheet-helix motif of p53. Am J Pathol 1999;155:955-65.
14. Liu J, Yang XY, Shi WJ. Identifying differentially expressed genes and pathways in two types of non-small cell lung cancer: adenocarcinoma and squamous cell carcinoma. Genet Mol Res GMR 2014;13:95-102.
15. Kara O, Duman BB, Kara B, Erdogan S, Parsak CK, Sakman G. Analysis of PTEN, VEGF, HER2 and P53 status in determining colorectal cancer benefit from bevacizumab therapy. Asian Pac J Cancer Prev APJCP 2012;13:6397-401.
16. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005;97:981-9.
17. Sato S, Itamochi H. Bevacizumab and ovarian cancer. Curr Opin Obstet Gynecol 2012;24:8-13.
18. Wojnarowicz PM, Oros KK, Quinn MCJ, Arcand SL, Gambaro K, Madore J, et al. The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome. PLoS ONE 2012;7:e45484.
19. cbioportal [Internet]. Available from: http://www.cbioportal.org/publicportal/index.do
20. Ogita S, Tejwani S, Heilbrun L, Fontana J, Heath E, Freeman S, et al. Pilot phase II trial of bevacizumab monotherapy in nonmetastatic castrate-resistant prostate cancer. ISRN Oncol 2012;2012:242850